Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers will present data from clinical studies of Soliris
(eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders, at the 54th Annual Meeting of the American Society of Hematology (ASH). Abstracts summarizing these data are published on the ASH website and can be accessed using the links below. The ASH annual meeting will be held December 8-11, 2012, at the Georgia World Congress Center in Atlanta.
Soliris is approved in the US, European Union, Japan and other countries as the first and only treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), a debilitating, ultra-rare and life-threatening blood disorder, characterized by complement-mediated hemolysis (destruction of red blood cells). Soliris is also approved in the United States and European Union as the first and only treatment for patients with atypical hemolytic uremic syndrome (aHUS), a debilitating, ultra-rare, life-threatening and chronic genetic disorder characterized by complement-mediated thrombotic microangiopathy (blood clots in small vessels).
Soliris and PNH
The following abstracts will be presented in a poster session on Saturday, December 8, 2012 from 5:30 -7:30 p.m., Eastern Standard Time (EST):
Abstract 1260: “Long-Term Safety of Sustained Eculizumab Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria,” Szer, et al.
Abstract 1271: “Distribution of PNH Clone Sizes within High Risk Diagnostic Categories Among 481 PNH Positive Patients Identified by High Sensitivity Flow Cytometry,” Movalia and Illingworth.
Abstract 1273: “Risk of Thromboembolism in Patients with Paroxysmal Nocturnal
Hemoglobinuria Presenting with Both Clinical Symptoms and Elevated Hemolysis,” Lee, et al.
The following abstracts will be presented in a poster session on Monday, December 10, 2012 from 6:00 – 8:00 p.m., EST: